Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Long-Term Deferred Tax: 2009-2010

Historic Long-Term Deferred Tax for Cytokinetics (CYTK) over the last 2 years, with Dec 2010 value amounting to $150.6 million.

  • Cytokinetics' Long-Term Deferred Tax rose 11.55% to $150.6 million in Q4 2010 from the same period last year, while for Dec 2010 it was $150.6 million, marking a year-over-year increase of 11.55%. This contributed to the annual value of $150.6 million for FY2010, which is 11.55% up from last year.
  • According to the latest figures from FY2010, Cytokinetics' Long-Term Deferred Tax is $150.6 million, which was up 11.55% from $135.0 million recorded in FY2009.
  • In the past 5 years, Cytokinetics' Long-Term Deferred Tax ranged from a high of $150.6 million in FY2010 and a low of $135.0 million during FY2009.
  • Its 2-year average for Long-Term Deferred Tax is $142.8 million, with a median of $142.8 million in 2009.
  • Data for Cytokinetics' Long-Term Deferred Tax shows a peak YoY increased of 11.55% (in 2010) over the last 5 years.
  • Cytokinetics' Long-Term Deferred Tax (Yearly) stood at $135.0 million in 2009, then increased by 11.55% to $150.6 million in 2010.